Reckitt Benckiser pays $1.4 billion in opioid settlement

LONDON — Consumer products company Reckitt Benckiser says it will pay $1.4 billion to resolve U.S. investigations into the marketing of an anti-addiction drug by a subsidiary.

The company said Thursday it reached agreements with the U.S. Department of Justice and the Federal Trade Commission.

The government alleged that an ex-Reckitt subsidiary sought to increase prescriptions for Suboxone Film by deceiving health care providers into believing the drug was safer than other opioid addiction treatments.

Suboxone Film was marketed by RB's former prescription business Indivior, which was spun off in 2014.

The company says it "acted lawfully at all times and expressly denies all allegations that it engaged in any wrongful conduct" but the settlement was in the best interest of RB and shareholders.

It said the settlement would prevent uncertainty and distraction from continued investigations.

You may also interested in

China plans 30,000-km high speed rail network by...

Dec 29, 2016

The Chinese government is planning to expand the country's high-speed rail network to 30,000...

Argentine soccer star Carlos Tevez signs $40M...

Dec 29, 2016

Argentine striker Carlos Tevez has signed to play for Shanghai Shenhua, becoming the latest in a...

China starts 2017 engulfed by smog, issues...

Jan 2, 2017

Beijing and other cities across northern and central China are shrouded in thick smog, prompting...

DEA opens shop in China to help fight synthetic...

Jan 6, 2017

The U.S. Drug Enforcement Administration plans to open a new office in southern China and, at...

China pledges further cuts in excess steel, coal...

Jan 10, 2017

China's top economic planner has pledged to continue cutting steel and coal production, which have...

About Us

Frontal Report is an emerging leader in all forms of media. We aim to be the leading news brand for readers around the world.

Contact us: sales[at]frontalreport.com

Subscribe Now!